HIGH-DOSE METHOTREXATE - A CRITICAL REAPPRAISAL

被引：229

作者：

ACKLAND, SP ^{[1
]}

SCHILSKY, RL ^{[1
]}

机构：

[1] UNIV CHICAGO, MED CTR, JOINT SECT HEMATOL ONCOL, CHICAGO, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1987年 / 5卷 / 12期

关键词：

D O I：

10.1200/JCO.1987.5.12.2017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2017 / 2031

页数：15

共 165 条

[1]

ABELSON HT, 1981, CANCER TREAT REP, V65, P137

[2]

ALLEGRA CJ, 1986, P AM ASSOC CANC RES, V27, P258

[3]

ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478

[4]

ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720

[5]

ALT FW, 1978, J BIOL CHEM, V253, P1357

[6]

ANDREWS NEIL C., 1967, CANCER CHEMOTHER REP, V51, P471

[7]

ANZAI T, 1986, P AM ASSOC CANC RES, V27, P255

[8] CHARACTERISTICS OF METHOTREXATE POLYGLUTAMATE FORMATION IN CULTURED HEPATIC CELLS [J].

BALINSKA, M ;

NIMEC, Z ;

GALIVAN, J .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1982, 216 (02) :466-476

[9]

BALINSKA M, 1981, CANCER RES, V41, P2751

[10] REMISSION INDUCTION OF MENINGEAL LEUKEMIA WITH HIGH-DOSE INTRAVENOUS METHOTREXATE [J].

BALIS, FM ;

SAVITCH, JL ;

BLEYER, WA ;

REAMAN, GH ;

POPLACK, DG .

JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (04) :485-489

← 1 2 3 4 5 6 7 8 9 10 →